Elevated Chitotriosidase Differentially Diagnoses Lysosomal Storage Disorders
By LabMedica International staff writers Posted on 25 May 2016 |
Image: A bone marrow aspirate biopsy of a patient with Gaucher Disease; the cytoplasm has wrinkled tissue paper appearance (Photo courtesy of the American Society of Hematology).
Plasma chitotriosidase originates from activated macrophages and is reported to be elevated in many Lysosomal Storage Disorders. Measurement of this enzyme’s activity has been an available tool for monitoring therapy of Gaucher disease.
The degree of elevation of chitotriosidase is useful for differential diagnosis of Gaucher disease and Niemann Pick A/B. However the potential utility of this chitotriosidase assay depends on the frequency of deficient chitotriosidase activity in a particular population.
Scientists at Sandor Life Sciences (Hyderabad, India) studied the clinical utility of this assay for Gaucher and Niemann Pick A/B diseases in the backdrop of chitotriosidase deficiency in a local population. The study comprises 173 patients with clinical suspicion of 108 with Gaucher disease or 65 with Niemann Pick A/B and 92 healthy controls.
The scientists found that the plasma samples of controls, Gaucher disease, and Niemann Pick A/B showed chitotriosidase deficiency of 12%, 25% and 27% respectively. The degree of elevation of chitotriosidase in Gaucher disease was 40 to 326 fold (11,325.7 ± 6395.4 nmol/h/mL) and in Niemann Pick A/B patients it was seven to 22 fold (1192.5 ± 463.0 nmol/h/mL). Chitotriosidase deficiency is observed in 22% of the Indian population.
Serum chitotriosidase (CHIT) enzymatic activity is usually determined with the flurometric enzyme activity assay using artificial 4-methylumbelliferyl- substrate. Normal mean and standard deviation CHIT activity in elderly people has been reported as 270 ± 21 nmol/h/mL and in young people as 136 ± 17 nmol/h/mL, but in some individuals no enzyme activity has been observed.
The authors concluded that their findings of distinguishable fold elevation of chitotriosidase in Gaucher disease or Niemann Pick A/B can be a potential surrogate differential diagnostic marker for these groups of diseases, except in the patients in whom this enzyme is deficient. The study was published in the June 1, 2016, issue of the journal Clinica Chimica Acta.
Related Links:
Sandor Life Sciences
The degree of elevation of chitotriosidase is useful for differential diagnosis of Gaucher disease and Niemann Pick A/B. However the potential utility of this chitotriosidase assay depends on the frequency of deficient chitotriosidase activity in a particular population.
Scientists at Sandor Life Sciences (Hyderabad, India) studied the clinical utility of this assay for Gaucher and Niemann Pick A/B diseases in the backdrop of chitotriosidase deficiency in a local population. The study comprises 173 patients with clinical suspicion of 108 with Gaucher disease or 65 with Niemann Pick A/B and 92 healthy controls.
The scientists found that the plasma samples of controls, Gaucher disease, and Niemann Pick A/B showed chitotriosidase deficiency of 12%, 25% and 27% respectively. The degree of elevation of chitotriosidase in Gaucher disease was 40 to 326 fold (11,325.7 ± 6395.4 nmol/h/mL) and in Niemann Pick A/B patients it was seven to 22 fold (1192.5 ± 463.0 nmol/h/mL). Chitotriosidase deficiency is observed in 22% of the Indian population.
Serum chitotriosidase (CHIT) enzymatic activity is usually determined with the flurometric enzyme activity assay using artificial 4-methylumbelliferyl- substrate. Normal mean and standard deviation CHIT activity in elderly people has been reported as 270 ± 21 nmol/h/mL and in young people as 136 ± 17 nmol/h/mL, but in some individuals no enzyme activity has been observed.
The authors concluded that their findings of distinguishable fold elevation of chitotriosidase in Gaucher disease or Niemann Pick A/B can be a potential surrogate differential diagnostic marker for these groups of diseases, except in the patients in whom this enzyme is deficient. The study was published in the June 1, 2016, issue of the journal Clinica Chimica Acta.
Related Links:
Sandor Life Sciences
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data